<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044954</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069461</org_study_id>
    <secondary_id>UTSMC-0799296</secondary_id>
    <secondary_id>AMGEN-UTSMC-0799296</secondary_id>
    <secondary_id>IBMTR-SC-00-03.1</secondary_id>
    <secondary_id>ROCHE-UTSMC-0799296</secondary_id>
    <secondary_id>SPRI-UTSMC-0799296</secondary_id>
    <secondary_id>NCI-V02-1705</secondary_id>
    <nct_id>NCT00044954</nct_id>
  </id_info>
  <brief_title>Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Low Dose Total-Body Irradiation And Fludarabine Followed By HLA Matched Allogeneic Stem Cell Transplantation For Hematologic Malgnancies - A Multi-Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in&#xD;
      chemotherapy use different ways to stop cancer cells from dividing so they stop growing or&#xD;
      die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the&#xD;
      doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining total-body irradiation with&#xD;
      fludarabine and donor peripheral stem cell transplantation in treating patients who have&#xD;
      hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate and duration of response in patients with low-risk&#xD;
           hematologic malignancies treated with low-dose total-body irradiation (TBI) and&#xD;
           fludarabine followed by HLA-matched allogeneic stem cell transplantation followed by a&#xD;
           slow immunosuppression taper and donor leukocyte infusions (DLI).&#xD;
&#xD;
        -  Determine the response rate and duration of response in patients with high-risk&#xD;
           hematologic malignancies treated with low-dose TBI and fludarabine followed by&#xD;
           HLA-matched allogeneic stem cell transplantation followed by a faster immunosuppression&#xD;
           taper and DLI.&#xD;
&#xD;
        -  Determine the incidence and extent of graft-versus-host disease, regimen-related&#xD;
           toxicity, and engraftment in patients treated with these regimens.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups (high-risk vs&#xD;
      low-risk hematologic malignancy). The high-risk group includes acute myelogenous leukemia,&#xD;
      myelodysplastic syndromes, accelerated phase chronic myelogenous leukemia (CML), second&#xD;
      chronic phase CML, and non-Hodgkin's lymphoma. The low-risk group includes Hodgkin's&#xD;
      lymphoma, first chronic phase CML, multiple myeloma, and chronic lymphocytic leukemia.&#xD;
&#xD;
      Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on&#xD;
      day 0 followed by allogeneic stem cell transplantation. Patients also receive oral&#xD;
      mycophenolate mofetil on days 0-28.&#xD;
&#xD;
      High-risk patients receive oral cyclosporine twice daily on days -2 to day 60. Patients with&#xD;
      persistent disease, T-cell chimerism, and no graft-vs-host disease (GVHD) on day 90 receive&#xD;
      up to 3 doses of donor leukocyte infusion (DLI) over the next 4 months.&#xD;
&#xD;
      Low-risk patients receive oral cyclosporine twice daily on days -2 to day 150. Patients with&#xD;
      persistent disease, T-cell chimerism, and no GVHD on day 180 receive up to 3 doses of DLI&#xD;
      over the next 4 months.&#xD;
&#xD;
      Quality of life is assessed at baseline and at 1, 3, 6, 9, 12, 18, and 24 months.&#xD;
&#xD;
      Patients are followed at 1, 3, 6, 9, and 12 months and then annually for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 120 patients (60 per group) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1999</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following hematologic malignancies:&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML)&#xD;
&#xD;
                    -  First or second chronic phase&#xD;
&#xD;
                    -  Accelerated phase&#xD;
&#xD;
               -  Acute myelogenous leukemia (AML)&#xD;
&#xD;
                    -  At least second remission&#xD;
&#xD;
                    -  First remission allowed if poor-risk features are present (complex&#xD;
                       chromosome karyotype, abnormalities of chromosomes, especially 5 or 7, 12p-,&#xD;
                       +13, +8, t[9:11])&#xD;
&#xD;
               -  Myelodysplastic syndromes (MDS)&#xD;
&#xD;
                    -  Intermediate- or high-risk disease by the prognostic scoring system&#xD;
&#xD;
               -  Multiple myeloma (MM)&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
                    -  Second or greater relapse&#xD;
&#xD;
                    -  First relapse allowed if disease-free interval is less than 1 year&#xD;
&#xD;
                    -  Ineligible for autologous transplantation&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
                    -  Grade III follicular large cell (relapsed after one course of prior&#xD;
                       chemotherapy)&#xD;
&#xD;
                    -  Diffuse large cell (relapsed after one course of prior chemotherapy)&#xD;
&#xD;
                    -  Mantle cell&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
                    -  Relapsed after at least 1 course of prior therapy&#xD;
&#xD;
          -  Must have 6 out of 6 HLA A-, B-, and DR- identical sibling donor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 75 for patients with MM&#xD;
&#xD;
          -  50 to 75 for patients with CML, AML, MDS, Hodgkin's lymphoma, NHL, or CLL&#xD;
&#xD;
          -  18 to 49 for patients with CML, AML, MDS, Hodgkin's lymphoma, NHL, or CLL who are&#xD;
             considered eligible for an allogeneic bone marrow transplantation (BMT) but do not&#xD;
             meet institutional criteria for a standard allogeneic BMT&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 3 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 40% by MUGA or echocardiogram&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO at least 50% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No recent history of drug or alcohol abuse&#xD;
&#xD;
          -  No other prior malignancy except basal cell skin cancer&#xD;
&#xD;
          -  No uncontrolled bacterial, viral, fungal, or parasitic infections&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior autologous transplantation allowed if disease progression occurred&#xD;
&#xD;
          -  No prior or concurrent tandem autologous transplantation followed by&#xD;
             non-myeloablative-allograft protocol&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert H. Collins, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Denver Midtown</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342-4777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers - Central</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-8590</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center at Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

